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After organ transplantation, susceptibility to cancer is
multifactorial, especially for skin carcinomas. Risk fac-
tors may include genetic susceptibilities, such as the
control of cytokine production. Interleukin-10 is a cy-
tokine that is implicated in tumorigenesis, and it has
been shown that polymorphisms in its gene promoter
correlate with di¡erential amounts of production. The
aim of this study was to investigate a possible associa-
tion between interleukin-10 gene promoter poly-
morphisms and the occurrence of skin carcinomas
after renal transplantation. Seventy kidney transplant
recipients who developed a squamous cell carcinoma
or a basal cell carcinoma were examined for poly-
morphisms in the interleukin-10 gene promoter using
polymerase chain reaction based methods. Single base
pair mutations were studied at positions ^1082, ^819,
and ^592. These patients were compared to 70 healthy
controls and to 70 matched renal transplant recipients
without cancer. The interleukin-10 secretion capability
was tested in a subgroup of 40 of these patients by in
vitro stimulation of peripheral mononuclear cells. Inter-
leukin-10 genotypes and haplotypes were di¡erently
distributed in kidney transplant recipients who devel-
oped a skin carcinoma, but especially a squamous cell
carcinoma, with an increased frequency of the GCC
haplotype and a decreased frequency of the ATA haplo-
type. Subsequently, we found a shift in the predicted
phenotypes from the low production phenotype to the
high production phenotype. Secretion of interleukin-10
was strongly correlated to the production predicted
phenotype, and tended to be higher in patients who de-
veloped a squamous cell carcinoma than in the others.
These results indicate that interleukin-10 gene poly-
morphisms and interleukin-10 production capability
may contribute to the development of skin squamous
cell carcinomas after renal transplantation. Key words:
gene polymorphism/interleukin-10/renal transplantation/skin
carcinomas. J Invest Dermatol 120:99 ^103, 2003
M
alignancies occur in at least 20% of transplant
recipients within 20 y after grafting. This risk
reaches 40% in certain studies (London et al,
1995). Among them, skin carcinomas account
for up to 50%. Some viruses, such as papilloma-
viruses, Epstein Barr virus, and human herpesvirus-8, are in-
volved in the pathogenesis of post-transplant tumors, especially
in the cases of skin tumors, B-cell lymphomas, and Kaposi’s sar-
comas. The conjunction of impaired immune defenses and viral
infections seems to be the trigger of tumorigenesis after organ
transplantation. Heavy immunosuppression, use of polyclonal
and monoclonal antibodies, high doses of cyclosporinee, and
splenectomy have been linked to a higher rate of cancer. Other
clinical risk factors for the occurrence of these malignancies have
also been identi¢ed. These are mainly age at transplantation,
duration of transplantation, sun exposure, and smoking. Genetic
risk factors are suspected although less documented. The male
gender has been suspected to be a risk factor and Kaposi’s sarcoma
a¡ects mainly people from the Mediterranean area. In regard to
skin carcinomas, human leukocyte antigen polymorphism
(Bouwes Bavinck et al, 1991) and genetic variations in the glu-
tathione S-transferase (Marshall et al, 2000) could confer suscept-
ibility.
Levels of cytokine production seem critical during autoim-
mune disorders (Bouma et al, 1996), tumorigenesis (Zheng et al,
1996), and organ transplantation (Awad et al, 1998). Genetic varia-
tions that a¡ect the production of cytokines could have an im-
portant e¡ect on tumorigenesis after organ transplantation.
Interleukin-10 (IL-10) is produced primarily by T helper type 2
lymphocytes and downregulates the Th1 pathway. IL-10 inhibits
macrophage-dependent antigen presentation; IL-10 induces T cell
energy and downregulates major histocompatibility complex
class II expression. IL-10 might therefore play a role in the induc-
tion of antigen-speci¢c tolerance (Mosmann, 1994; Groux et al,
1996; Kundu and Fulton, 1997). Moreover, ultraviolet-induced
DNA damage, which triggers the transformation of keratino-
cytes, increases the production of IL-10 (Nishigori et al, 1996).
Polymorphisms in cytokine gene promoters alter the produc-
tion of mRNAs, and hence the amount of proteins. The gene en-
coding for IL-10 has been mapped on chromosome 1. Several
polymorphisms that in£uence IL-10 production have been
described in the IL-10 gene promoter region (Turner et al, 1997;
Eskdale et al, 1998; D’Alfonso et al, 2000). In fact, three bi-allelic
polymorphisms were found to be in strong linkage desequili-
brium. Three single base pair mutations have been described: a
G to A substitution at position ^1082, a C toT substitution at po-
sition ^819, and a C to A substitution at position ^592. Three out
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of the eight possible haplotypes, i.e., GCC, ACC, and ATA,
segregate in the general population (Turner et al, 1997).
In this study, we investigated a possible relationship between
IL-10 gene polymorphisms and the occurrence of skin carcino-
mas following renal transplantation.
MATERIALS AND METHODS
Patients Among a cohort of 879 consecutive renal transplant recipients
grafted in our center from 1979 to 1999, 87 developed at least one skin
carcinoma. DNA was available for 70 of them who were all included in
the genetic study. All the patients gave their formal agreement for a
genomic study but no speci¢c ethical approval was required, as the
Ministry of Health has given our center authorization for genetic studies.
These 70 patients were compared to 70 normal controls (healthy volunteers
matched for gender) and to 70 transplant recipients without any cancer
(una¡ected patients). The latter were matched for year of transplantation,
type of immunosuppression, gender, and age at grafting. Every transplant
recipient is given repeated information on the danger of ultraviolet
exposure and is asked to attend a yearly skin examination by a
dermatologist. The tumors were 40 squamous cell carcinomas (SCC) and
30 basal cell carcinomas (BCC). The diagnosis was con¢rmed by
histopathology in all cases. Patients with an SCC or a BCC were
compared to controls, to una¡ected patients, and between them. We
analyzed the distributions of the genotypes and of the haplotypes.We also
classi¢ed the predicted level of cytokine production according to their
polymorphisms. GCC homozygous patients were considered as high
producers (i.e., GCC/GCC genotype), GCC heterozygous patients as
intermediate producers (i.e., GCC/ATA and GCC/ACC genotypes), and
GCC negative patients as low producers (i.e., ATA/ATA, ACC/ATA, and
ACC/ACC genotypes) (Turner et al, 1997).
Preparation of genomic DNA Genomic DNA from whole fresh
peripheral mononuclear cells was obtained by a phenol chloroform
extraction and ethanol precipitation. Unless speci¢ed, polymerase
chain reaction (PCR) ampli¢cation of 250 ng DNA was done with
1.25 University of Thermus Aquaticus DNA polymerase (Gibco BRL,
Carlsbad, CA) in 20 mM Tris^HCl containing 50 mM KCl, 2.5 mM
MgCl2, 200 mM dNTP, and 0.5 mM of each primer.
Genotyping IL-10 gene promoter polymorphisms We performed a
¢rst ampli¢cation with 0.025 mM primers surrounding the three positions,
^1082, ^819, and ^592.The sense primer was 50 -ATC CAAGACAACACT
ACT AA-30 and the antisense primer was 50 -TAA ATA TCC TCA AAG
TTC C-30.We proceeded to a second ampli¢cation for each position. The
^1082 position was analyzed by a nested PCR restriction fragment length
polymorphism. Fragments of the previous PCRwere ampli¢ed with a 50 -
ATC CAA GAC AAC ACTACTAA-50 sense primer and a 50 -GTG GAA
GAA GTT GAA ATA AC-30 antisense primer. Fragments were then
digested with Mnl-1 for a restriction fragment length polymorphism
analysis and run on an 8% polyacrylamide gel. Allele Awas characterized
by two bands of 38 and 80 bp, and allele G by three bands of 24, 38, and 56
bp (Fig 1). For the ^819 position, products of the ¢rst PCRwere digested
during 3 h at 551C with Mae-III and run on an 8% polyacrylamide gel.
Allele C was characterized by three bands of 79, 217, and 292 bp, and
allele T by two bands of 79 and 509 bp (Fig 2). For the ^592 position,
products of the ¢rst PCR were digested during 3 h at 371C with Rsa-I
and run on an 8% polyacrylamide gel (Fig 3). Allele C was characterized
by three bands of 42, 232, and 306 bp, and allele A by four bands of 42, 66,
232, and 240 bp.
IL-10 secretion Peripheral blood was drawn into heparinized tubes and
mononuclear cells (PBMC) were harvested after FicollHypaque gradient
centrifugation. PBMC were incubated at a concentration of 2106 per ml
in 24-well plates. Medium consisted of RPMI-1640 supplemented with
10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. Stimulation
was obtained by adding lipopolysaccharide (Escherichia coli extract, 055:B5,
Sigma, St. Louis, MO) at a concentration of 1 mg per ml, during an 18 h
incubation at 371C, 5% CO2. Supernatants were harvested for immediate
freezing at 701C. IL-10 was measured in supernatants by immunoassay
with Quantikine HS (R&D Systems, Abingdon, UK).
Statistical analysis The data were analyzed using a w2 test; Fisher’s exact
test was applied when one of the expected values was less than 5; relative
risks and odds ratios were calculated with their 95% con¢dence intervals.
Continuous variables were analyzed by t test and ANOVA.
RESULTS
Patients’ characteristics We tried to match the patients as well
as possible in order to make patients with a skin carcinoma
comparable to those without. In these two groups, we obtained
the same distribution of gender (54 vs 49 males, p¼ 0.33), but
age at grafting was higher in cancer patients (51711 vs 42711 y,
p¼ 0.0001). Original renal diseases were similar in the two
groups, as well as number of second transplants (10 in both
groups), peak reactive antibodies level (15% vs 14%), induction
with antithymocyte globulins (31% vs 34%), and total amount
of immunosuppression. The latter was assessed by the number
of treatments given to each patient, with antithymocyte
globulins or boluses of methyl prednisolone, as either induction
therapy or antirejection therapy. The mean transplant follow-up
duration was 115761 mo in patients with a skin carcinoma and
120743 mo in una¡ected patients (NS). SCC were discovered
after a mean duration of 58739 mo, and BCC after 63735 mo
(NS).
Distribution of the genotypes The IL-10 genotypes were
unequally distributed between cancer patients, una¡ected
patients, and controls (Table I, p¼ 0.001). The distribution was
Figure1. Polyacrylamide gel of the ^1082 mutation in the IL-10
gene promoter. Allele A is indicated by the 80 bp band and allele G by
the 56 bp band.
Figure 2. Polyacrylamide gel of the ^819 mutation in the IL-10 gene
promoter. Allele C is indicated by the 217 and 292 bp bands, allele T by
the 509 bp band.
Figure 3. Polyacrylamide gel of the ^592 mutation in the IL-10 gene
promoter. Allele C is indicated by the 306 bp band and allele G by the
240 bp band.
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also di¡erent when cancer patients were compared to una¡ected
patients (p¼ 0.006), or when patients with an SCC were
compared to una¡ected patients (p¼ 0.003). Patients with a BCC
did not di¡er from una¡ected patients or from patients with an
SCC. We note that the distribution of these genotypes was
di¡erent between una¡ected patients and controls but with a
borderline signi¢cance (p¼ 0.016).
Distribution of the haplotypes These di¡erences were
easier to acknowledge with the distribution of the haplotypes
(Table II). Cancer patients, una¡ected patients, and controls
were altogether di¡erent (p¼ 0.0009). This was due to the lower
frequency of the ATA haplotype in kidney transplant recipients
with a skin carcinoma (15%), either SCC (14%) or BCC (17%),
than in una¡ected patients (24%) and in controls (31%). In
parallel, we found a higher frequency of the GCC haplotype in
patients with a skin carcinoma (51%), either SCC (56%) or BCC
(43%), than in una¡ected patients (32%) and in controls (42%).
The haplotype distribution was signi¢cantly di¡erent when
cancer patients were compared to controls (p¼ 0.007) and to
una¡ected patients (p¼ 0.006), or when patients with an SCC
were compared to una¡ected patients (p¼ 0.003). Patients with a
BCC did not di¡er from una¡ected patients, or from patients
with an SCC.
Distribution of the production predicted phenotypes The
production predicted phenotypes were also unequally
distributed between cancer patients, una¡ected patients, and
controls (p¼ 0.038,Table III). The phenotype associated with a
low production of IL-10 (GCC negative patients) was less
frequent in cancer patients (23% vs 47% in una¡ected patients),
but only in the patients with an SCC (12%) and not in the case
of patients with a BCC (37%). The phenotype associated with a
high production of IL-10 (GCC homozygous patients) was more
frequent in cancer patients (24% vs 11% in una¡ected patients),
either SCC (25%) or BCC (23%). The comparisons were
signi¢cant between cancer patients and una¡ected patients
(p¼ 0.006) and between patients with an SCC and una¡ected
patients (p¼ 0.0009). Once again, the patients with a BCC did
not di¡er from una¡ected patients.
In cancer patients with an SCC, the frequency of the low
predicted phenotype was compared to that of high and
intermediate predicted phenotypes. The odds ratio was 0.16 (95%
con¢dence interval, 0.06^0.42) and the relative risk was 0.27,
indicating a protective e¡ect of the low predicted phenotype.
When the frequency of the high predicted phenotype was
compared to that of intermediate or low predicted pheno-
types, we found an odds ratio of 2.58 (95% con¢dence interval,
1.05^7.04). The relative risk was 1.7, indicating a deleterious e¡ect
of the high predicted phenotype.
In vitro secretion of IL-10 The IL-10 production capacity was
investigated in a subpopulation of 40 of these transplant
recipients. Secretion of IL-10 was compared according to the
production predicted phenotypes as de¢ned by genetic analysis.
After stimulation by lipopolysaccharide, the secretion of IL-10
was signi¢cantly di¡erent in the high, medium and low
predicted phenotypes with 13117585 pg per ml, 736þ 536 pg
per ml, and 4497250 pg per ml, respectively (Fig 4)
(ANOVA, p¼ 0.0002). These data indicated a strong relation-
ship between gene polymorphisms and IL-10 secretion in
individuals. Of the 40 patients 16 were una¡ected patients, 17
were patients with an SCC, and seven were patients with
a BCC. The mean production of IL-10 was 6497491 pg per ml
in una¡ected patients, 9177685 pg per ml in patients with
an SCC, and 6997282 pg per ml in patients with a BCC
(Fig 5). Although IL-10 secretion was higher in the
patients with an SCC, the di¡erence did not reach statistical
signi¢cance.
Table I. IL-10 genotypes
Genotypes
ACC/ACC ACC/ATA ATA/ATA GCC/ACC GCC/ATA GCC/GCC
Controls 70 4 (6) 12 (17) 8 (11) 18 (26) 15 (21) 13 (19)
Una¡ected patientsa 70 17 (24) 14 (20) 2 (3) 13 (19) 16 (23) 8 (11)
Cancer patientsb 70 6 (9) 9 (13) 1 (1) 27 (39) 10 (14) 17 (24)
Squamous cell carcinomasc 40 2 (5) 3 (8) 0 (0) 17 (42) 8 (20) 10 (25)
Basal cell carcinomas 30 4 (13) 6 (20) 1 (3) 10 (33) 7 (23) 7 (23)
Point mutations at positions ^1082 (A-G), ^819 (T-C), and ^592 (A-C) in the IL-10 gene promoter are responsible for the common GCC, ACC, and ATA
combinations.
Results are given as numbers and percentages (in parentheses).
ap¼ 0.016 vs controls.
bp¼ 0.006 vs una¡ected patients.
cp¼ 0.003 vs una¡ected patients.
Table II. IL-10 haplotypes
Haplotypes
GCC ACC ATA
Controls 140 59 (42) 38 (27) 43 (31)
Una¡ected patientsa 140 45 (32) 61 (44) 34 (24)
Cancer patientsb 140 71 (51) 48 (34) 21 (15)
Squamous cell carcinomasc 80 45 (56) 24 (30) 11 (14)
Basal cell carcinomas 60 26 (43) 24 (40) 10 (17)
The three haplotypes that segregate in the general population (GCC, ACC, and
ATA) are indicated.
Results are given as numbers and percentages (in parentheses).
ap¼ 0.015 vs controls.
bp¼ 0.006 vs una¡ected patients and 0.007 vs controls.
cp¼ 0.003 vs una¡ected patients.
Table III. Predicted phenotypes of IL-10 production
Predicted phenotypes
High Intermediate Low
Controls 70 13 (19) 33 (47) 24 (34)
Una¡ected patients 70 8 (11) 29 (41) 33 (47)
Cancer patientsa 70 17 (24) 37 (53) 16 (23)
Squamous cell carcinomasb 40 10 (25) 25 (63) 5 (12)
Basal cell carcinomas 30 7 (23) 12 (40) 11 (37)
GCC homozygous patients were considered as high producers, GCC heterozy-
gous patients as intermediate producers, and GCC negative patients as low produ-
cers.
Results are given as numbers and percentages (in parentheses).
ap¼ 0.006 vs una¡ected patients.
bp¼ 0.0009 vs una¡ected patients.
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DISCUSSION
Cancer is a potentially remediable aberration in the continuum of
normal cell regulation. A great number of cancers are associated
with human viruses, although the virus infection is not su⁄cient
per se. Immunosuppression, inhibition of apoptosis, and tolerance
to tumor antigens may contribute to tumorigenesis after trans-
plantation (Birkeland and Bendtzen, 1996). Because of their im-
munomodulatory e¡ects and their action on viral open reading
frames, cytokines are supposed to play a role in tumorigenesis.
As there is growing evidence for a genetic basis of cancer (Haber
and Fearon, 1998), much attention is being paid to the genetic
control of cytokine production.
We should be aware of the limits of investigations on associa-
tion with genetic polymorphisms. The phenotypic heterogeneity
of the disease, the insu⁄cient number of cases, the possible neu-
tral e¡ect of the studied allele, and the missing of a truly relevant
polymorphism are the pitfalls of these studies (Gambaro et al,
2000). Many other polymorphisms have been described in asso-
ciation with skin cancer. Glutathione S-transferase is a group of
antioxidant enzymes that protect against ultraviolet-mediated
DNA damage. A polymorphism at the glutathione S-transferase
locus GSTM3 was found in association with cutaneous BCC in
immunocompetent people (Yengi et al, 1996), and also in immu-
nocompromised patients (Marshall et al, 2000). The E6 oncopro-
tein derived from human papillomaviruses binds to and induces
the degradation of the tumor suppressor protein p53. A common
polymorphism that occurs in the p53 sequence, which results in
the presence of an arginine instead of a proline at position 72,
seems to favor human papillomavirus-associated cancers (Storey
et al, 1998), although other studies have challenged this hypothesis
(Marshall et al, 2000; O’Connor et al, 2001). A polymorphism in
tumor necrosis factor a microsatellite has been related to an
increased risk of multiple BCC (Hajeer et al, 2000). Lastly, the
melanocortin-1-receptor gene variants, which are known to be
associated with melanoma, have been found to be associated with
nonmelanoma skin cancer (Bastaiens et al, 2001; Box et al, 2001).
In this study, the patients’ characteristics were the same except
for a 10 y di¡erence in age at grafting. Although we tried to
match the patients as well as possible, choosing several parameters
made us fail this goal. Gender distribution was similar as well as
the type and the amount of immunosuppression, which is a ma-
jor factor for the occurrence of cancer after organ transplantation.
We did not assess sun exposure, but all the patients lived in a
common geographic area. Counseling and dermatologic exami-
nation were the same for all transplant recipients. The distribu-
tions of the genotypes and haplotypes between una¡ected
patients and controls were slightly unequal but this does not jeo-
pardize our results. Indeed, the genotypes and the three main
haplotypes, i.e., GCC, ACA, and ATA, were not equally distrib-
uted when comparison was done between una¡ected patients and
cancer patients, with a shift from the ATA to the GCC haplotype.
Hence, we found a relationship between IL-10 polymorphism
and post-transplant cutaneous carcinomas. Of greater functional
relevance, the low production phenotype was less frequent in
cancer patients, whereas the high production phenotype was
more frequent. All these results were in fact obtained only in the
group of patients with an SCC. Patients with a BCC were fewer
but these results may indicate a di¡erence in the response to IL-10
between SCC and BCC. As a whole, these data indicate that
IL-10 production might favor the occurrence of carcinoma in
transplanted patients, and especially of SCC.We did not examine
other polymorphisms that exist in the IL-10 gene and that also
a¡ect IL-10 production (Eskdale et al, 1996; D’Alfonso et al, 2000).
They could be implicated in post-transplant skin carcinomas.
The actual secretion of IL-10 was tested by a functional assay
in a subpopulation of 40 transplant recipients. These patients were
included only on the basis that it was possible to harvest fresh
blood from them. Signi¢cant di¡erences were found between
high, medium, and low predicted producers for IL-10, providing
further evidence that variation in the protein production within
individuals may result from genetic changes in cytokine genes.
We also compared the IL-10 secretion among cancer and unaf-
fected patients. We did not ¢nd a statistical di¡erence in these
maybe few patients but individuals with an SCC produced much
more IL-10 than the others. The distribution of IL-10 secretion
appeared to be wide in patients with an SCC (Fig 5) as well as
in individuals of the high production phenotype (Fig 4), which
could explain this lack of signi¢cance.
Due to its immunosuppressive and anti-in£ammatory proper-
ties, it has been hypothesized that IL-10 may contribute to the
escape of tumor cells from immune surveillance and favor tumor
growth. Many studies support a role for IL-10 in malignant cuta-
neous lesions. IL-10 levels are higher in the serum of patients with
advanced melanoma than in controls (Nemunaitis et al, 2001) and
metastatic melanoma cells preferentially produce IL-10 (Dummer
et al, 1996). Genotypes associated with high levels of IL-10 expres-
sion have been showed to be protective against cutaneous malig-
nant melanoma (Howell et al, 2001). The expression of IL-10
mRNA is downregulated in warts (Jackon et al, 1996) and the
production of IL-10 and its subsequent shift to a type 2 cytokine
production is associated with more extensive papillomavirus in-
fection in women with cervical carcinomas (Clerici et al, 1997).
Nevertheless, experiments in animals and humans yielded contra-
dictory results regarding the e¡ects of IL-10. For example, the
transfection of IL-10 in melanoma cells (Huang et al, 1999) or
mammary tumor cells (Kundu et al, 1996) resulted in a loss of
Figure 4. IL-10 secretion and production predicted phenotypes.
Box-plot representation of IL-10 concentration in the culture supernatant
of PBMC after lipopolysaccharide stimulation is given for high (gray),
medium (dashed), and low (white) predicted phenotypes.
Figure 5. IL-10 secretion and skin carcinomas. Box-plot representa-
tion of IL-10 concentration in the culture supernatant of PBMC after lipo-
polysaccharide stimulation is given for BCC patients (white), SCC patients
(gray), and una¡ected patients (dashed).
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metastasis and inhibition of tumor growth. Closer to skin carci-
nomas, IL-10 increased Th1 cytokine production and papilloma-
virus-speci¢c cytotoxic T lymphocytes in cervical cancer patients
(Santin et al, 2000). Therefore, the perception of IL-10 as solely an
immunosuppressive cytokine is being challenged. Investigations
have also been carried out during benign cutaneous disorders
such as psoriasis. They too led to contradictory results. No asso-
ciation was found with point mutations at position ^1082 (Reich
et al, 1999), whereas others found that polymorphism in the mi-
crosatellite regions contributes to susceptibility to the disease
(Asadullah et al, 2001).
In this study in kidney transplant recipients with skin carcino-
mas, we found that IL-10 genotypes and haplotypes were di¡er-
ently distributed, with an increased frequency of the GCC
haplotype and a decreased frequency of the ATA haplotype. The
distribution of the predicted phenotypes was shifted from the
low IL-10 production phenotype to the high IL-10 production
phenotype. These results a¡ected patients with an SCC, but not
those with a BCC. In vitro secretion of IL-10 by mononuclear
cells was strongly correlated to the production predicted pheno-
type, strengthening the known in£uence of genetic polymorph-
ism on cytokine production capability.We also found a trend for
a higher secretion of IL-10 in the patients with an SCC, although
great caution is required in interpreting this last result.We con-
clude that IL-10 production capability might make individuals
more susceptible to SCC after organ transplantation.
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